Roots Analysis is pleased to announce the publication of its recent study, titled, “Neoantigen Targeted Therapies, 2019-2030.”
The report features an extensive study of the current market landscape, offering an informed opinion on the likely adoption of these therapeutics over the next decade. It features an in-depth analysis, highlighting the capabilities of various stakeholders engaged in this domain. In addition to other elements, the study includes:
• A detailed assessment of the current market landscape of developers engaged in the development of neoantigen targeted therapies.
• Detailed profiles of developers of neoantigen targeted therapies (shortlisted on the basis of the number of pipeline products).
• A detailed publication analysis of close to 300 peer-reviewed, scientific articles published during the period 2015-2019 (till February), highlighting the research focus within the industry.
• An in-depth analysis of the various patents that have been filed / granted related to neoantigens.
• An analysis of the various partnerships pertaining to neoantigen targeting therapies.
• An analysis of the investments made at various stages of development in companies that are focused on developing neoantigen targeted therapies.
For more information, please visit https://www.rootsanalysis.com/reports/view_document/neoantigen-targeted-therapies-market-2019-2030/257.html
A detailed market forecast, featuring analysis of the current and projected future opportunity across key market segments (listed below)
Target Disease Indication
• Bone and Cartilage Cancer
• Colorectal Cancer
• Head and Neck Cancer
• Renal Carcinoma
• Hepatocellular Carcinoma
• Lung Cancer
• Gynecological Cancer
• Others
Type of Treatment
• Personalized
• Off-the-shelf
Type of Immunotherapy
• Dendritic Cell Vaccine
• DNA / RNA-based Vaccine
• Protein / Peptide-based Vaccine
• TIL-based Therapy
Route of Administration
• Intradermal
• Intravenous
• Subcutaneous
• Others
Key Geographical Region
• North America (US)
• Europe (UK, Germany, France, Italy, and Spain
• Rest of the World
Transcripts of interviews held with the following senior level representatives of stakeholder companies:
• Gabriel Nistor, Chief Scientific Officer, AIVITA Biomedical
• Ella Sorani, Vice President Research and Development, BioLineRx
• Heinz Lubenau, Chief Operating Officer and Co-Founder, VAXIMM
Key companies covered in the report
• Bavarian Nordic
• Genocea Biosciences
• Gradalis
• Immunicum
• Immunovative Therapies
• Iovance Biotherapeutics
• Medigene
• Neon Therapeutics
• Precision Biologics
• Vaxon Biotech
For more information, please click on the following link:
https://www.rootsanalysis.com/reports/view_document/neoantigen-targeted-therapies-market-2019-2030/257.html